Key result
Adriamycin administration significantly reduced the myocardial phosphocreatine-to-ATP ratio at 6 weeks (1.39 vs 1.79, P<0.05), preceding the onset of left ventricular dysfunction at 8 weeks.
Why the study?
Does Adriamycin administration impair myocardial high-energy phosphate metabolism prior to the onset of left ventricular dysfunction in mice?
Population
Adult male C57BL6 mice (weight 30-40 g), n=15 in the Adriamycin group.
Comparison
Adriamycin 5 mg/kg intraperitoneal injection… vs Normal saline intraperitoneal injection
Design
Preclinical
Follow-up
10 weeks
Authors
Loading...
Hypothesis-generating for energetic impairment preceding doxorubicin cardiotoxicity in mice; human relevance and therapeutic implications require clinical validation.
Does Adriamycin administration impair myocardial high-energy phosphate metabolism prior to the onset of left ventricular dysfunction in mice?
Absolute Event Rate: 1.39% vs 1.79%
p-value: p=<0.05
In vivo murine imaging demonstrates that Adriamycin-induced impairment of cardiac energetics precedes the onset of left ventricular dysfunction, suggesting a mechanistic role in cardiotoxicity.
Maslov et al. (2010) studied Adriamycin-induced cardiotoxicity (n=28). Adriamycin vs. Normal saline was evaluated on Mean myocardial phosphocreatine-to-ATP ratio (PCr/ATP) at 6 weeks (p=<0.05). Adriamycin administration significantly reduced the myocardial phosphocreatine-to-ATP ratio at 6 weeks (1.39 vs 1.79, P<0.05), preceding the onset of left ventricular dysfunction at 8 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: